Epstein-barr virus-associated lymphoid malignancies: The expanding spectrum of hematopoietic neoplasms

Nagoya Journal of Medical Science

Volumn 75, Issue 3-4, 2013, Pages 169-179

  Kimura, Hiroshi ^a   Kawada, Jun Ichi ^a   Ito, Yoshinori ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

EBV; Hydroa Vacciniforme Like Lymphoma; Latency; Systemic Ebv+ T Cell Lymphoproliferative Disease Of Childhood

Indexed keywords

B LYMPHOCYTE; BURKITT LYMPHOMA; CHILD; EPSTEIN BARR VIRUS; HEMATOLOGIC DISEASE; HUMAN; LYMPHOPROLIFERATIVE DISEASE; METABOLISM; PATHOLOGY; REVIEW; T LYMPHOCYTE; VIROLOGY;

B-LYMPHOCYTES; BURKITT LYMPHOMA; CHILD; HEMATOLOGIC NEOPLASMS; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; T-LYMPHOCYTES;

EID: 84883227730     PISSN: 00277622     EISSN: 21863326     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Rickinson AB, Kieff E. Epstein-Barr Virus and Its Replication. In: Knipe DM, Howly PM. Virology, 5th ed., vol. 2. pp. 2603-2654, 2006, Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia.
2. Cohen JI. Epstein-Barr virus infection. N Engl J Med, 2000; 343: 481-492.
3. Williams H, Crawford DH. Epstein-Barr virus: the impact of scientific advances on clinical practice. Blood, 2006; 107: 862-869.
4. Rickinson AB, Kieff E. Epstein-Barr Virus. In: Knipe DM, Howly PM. Virology, 5th ed., vol. 2. pp.2655-2700, 2006, Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia.
5. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet, 1964; 1: 702-703.
6. Cohen JI, Kimura H, Nakamura S, Ko YH, Jaffe ES. Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008. Ann Oncol, 2009; 20: 1472-1482.
7. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med, 2004; 350: 1328-1337.
8. Fingeroth JD, Weis JJ, Tedder TF, Strominger JL, Biro PA, Fearon DT. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci, USA 1984; 81: 4510-4514.
9. Spriggs MK, Armitage RJ, Comeau MR, Strockbine L, Farrah T, Macduff B, Ulrich D, Alderson MR, Mullberg J, Cohen JI. The extracellular domain of the Epstein-Barr virus BZLF2 protein binds the HLA-DR beta chain and inhibits antigen presentation. J Virol, 1996; 70: 5557-5563.
10. Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, Brenner MK, Rooney CM. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med, 1996; 2: 551-555.
11. Borza CM, Hutt-Fletcher LM. Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nat Med, 2002; 8: 594-599.
12. Tugizov SM, Berline JW, Palefsky JM. Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells. Nat Med, 2003; 9: 307-314.
13. Molesworth SJ, Lake CM, Borza CM, Turk SM, Hutt-Fletcher LM. Epstein-Barr virus gH is essential for penetration of B cells but also plays a role in attachment of virus to epithelial cells. J Virol, 2000; 74: 6324-6332.
14. Anagnostopoulos I, Hummel M, Kreschel C, Stein H. Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. Blood, 1995; 85: 744-750.
15. Hudnall SD, Ge Y, Wei L, Yang NP, Wang HQ, Chen T. Distribution and phenotype of Epstein-Barr virus-infected cells in human pharyngeal tonsils. Mod Pathol, 2005; 18: 519-527.
16. Kasahara Y, Yachie A, Takei K, Kanegane C, Okada K, Ohta K, Seki H, Igarashi N, Maruhashi K, Katayama K, Katoh E, Terao G, Sakiyama Y, Koizumi S. Differential cellular targets of Epstein-Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Blood, 2001; 98: 1882-1888.
17. Takahashi E, Asano N, Li C, Tanaka T, Shimada K, Shimada S, Yoshino T, Kojima M, Hara K, Eimoto T, Nakamura S. Nodal T/NK-cell lymphoma of nasal type: a clinicopathological study of six cases. Histopathology, 2008; 52: 585-596.
18. Tabiasco J, Vercellone A, Meggetto F, Hudrisier D, Brousset P, Fournie JJ. Acquisition of viral receptor by NK cells through immunological synapse. J Immunol, 2003; 170: 5993-5998.
19. Calattini S, Sereti I, Scheinberg P, Kimura H, Childs RW, Cohen JI. Detection of EBV genomes in plasmablasts/plasma cells and non-B cells in the blood of most patients with EBV lymphoproliferative disorders using Immuno-FISH. Blood, 2010; 116: 4546-4549.
20. Kis LL, Takahara M, Nagy N, Klein G, Klein E. Cytokine mediated induction of the major Epstein-Barr virus (EBV)-encoded transforming protein, LMP-1. Immunol Lett, 2006; 104: 83-88.
21. Tao Q, Robertson KD, Manns A, Hildesheim A, Ambinder RF. Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue. Blood, 1998; 91: 1373-1381.
22. Deacon EM, Pallesen G, Niedobitek G, Crocker J, Brooks L, Rickinson AB, Young LS. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med, 1993; 177: 339-349.
23. Young L, Alfieri C, Hennessy K, Evans H, O'Hara C, Anderson KC, Ritz J, Shapiro RS, Rickinson A, Kieff E, Cohen JI. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med, 1989; 321: 1080-1085.
24. Yoshioka M, Ishiguro N, Ishiko H, Ma X, Kikuta H, Kobayashi K. Heterogeneous, restricted patterns of Epstein-Barr virus (EBV) latent gene expression in patients with chronic active EBV infection. J Gen Virol, 2001; 82: 2385-2392.
25. Xue SA, Labrecque LG, Lu QL, Ong SK, Lampert IA, Kazembe P, Molyneux E, Broadhead RL, Borgstein E, Griffin BE. Promiscuous expression of Epstein-Barr virus genes in Burkitt's lymphoma from the central African country Malawi. Int J Cancer, 2002; 99: 635-643.
26. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed., 2008, WHO Press, Lyon.
27. Shimizu N, Tanabe-Tochikura A, Kuroiwa Y, Takada K. Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV. J Virol, 1994; 68: 6069-6073.
28. Leoncini L, Raphael M, Stein H, Harris NL, Jaffe ES, Kluin PM. Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed., pp.262-266, 2008, IARC Press, Lyon.
29. Burkitt D. A sarcoma involving the jaws in African children. Br J Surg, 1958; 46: 218-223.
30. Honjo T, Muramatsu M, Fagarasan S. AID: how does it aid antibody diversity? Immunity, 2004; 20: 659-668.
31. Xu Z, Zan H, Pone EJ, Mai T, Casali P. Immunoglobulin class-switch DNA recombination: induction, targeting and beyond. Nat Rev Immunol, 2012; 12: 517-531.
32. Robbiani DF, Bothmer A, Callen E, Reina-San-Martin B, Dorsett Y, Difilippantonio S, Bolland DJ, Chen HT, Corcoran AE, Nussenzweig A, Nussenzweig MC. AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. Cell, 2008; 135: 1028-1038.
33. He B, Raab-Traub N, Casali P, Cerutti A. EBV-encoded latent membrane protein 1 cooperates with BAFF/ BLyS and APRIL to induce T cell-independent Ig heavy chain class switching. J Immunol, 2003; 171: 5215-5224.
34. Kim JH, Kim WS, Park C. Epstein-Barr virus latent membrane protein 1 increases genomic instability through Egr-1-mediated up-regulation of activation-induced cytidine deaminase in B-cell lymphoma. Leuk Lymphoma, in press.
35. Osato T, Mizuno F, Imai S, Aya T, Koizumi S, Kinoshita T, Tokuda H, Ito Y, Hirai N, Hirota M, Koshimizu K, Kofi-Tsekpo WM, Were JBO, Mugamibi M. African Burkitt's lymphoma and an Epstein-Barr virusenhancing plant Euphorbia tirucalli. Lancet, 1987; 1: 1257-1258.
36. Molyneux EM, Rochford R, Griffin B, Newton R, Jackson G, Menon G, Harrison CJ, Israels T, Bailey S. Burkitt's lymphoma. Lancet, 2012; 379: 1234-1244.
37. Quintanilla-Martinez L, Kimura H, Jaffe ES. EBV+ T-cell lymphoma of childhood. In: Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed., pp.278-280, 2008,WHO Press, Lyon.
38. Ohshima K, Kimura H, Yoshino T, Kim CW, Ko YH, Lee SS, Peh SC, Chan JK. Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD. Pathol Int, 2008; 58: 209-217.
39. Kimura H, Ito Y, Kawabe S, Gotoh K, Takahashi Y, Kojima S, Naoe T, Esaki S, Kikuta A, Sawada A, Kawa K, Ohshima K, Nakamura S. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood, 2012; 119: 673-686.
40. Quintanilla-Martinez L, Kumar S, Fend F, Reyes E, Teruya-Feldstein J, Kingma DW, Sorbara L, Raffeld M, Straus SE, Jaffe ES. Fulminant EBV(+) T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. Blood, 2000; 96: 443-451.
41. Isobe Y, Aritaka N, Setoguchi Y, Ito Y, Kimura H, Hamano Y, Sugimoto K, Komatsu N. T/NK cell type chronic active Epstein-Barr virus disease in adults: an underlying condition for Epstein-Barr virus-associated T/NK-cell lymphoma. J Clin Pathol, 2012; 65: 278-282.
42. Kimura H, Hoshino Y, Kanegane H, Tsuge I, Okamura T, Kawa K, Morishima T. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood, 2001; 98: 280-286.
43. Kimura H, Morishima T, Kanegane H, Ohga S, Hoshino Y, Maeda A, Imai S, Okano M, Morio T, Yokota S, Tsuchiya S, Yachie A, Imashuku S, Kawa K, Wakiguchi H. Prognostic factors for chronic active Epstein- Barr virus infection. J Infect Dis, 2003; 187: 527-533.
44. Okano M, Kawa K, Kimura H, Yachie A, Wakiguchi H, Maeda A, Imai S, Ohga S, Kanegane H, Tsuchiya S, Morio T, Mori M, Yokota S, Imashuku S. Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection. Am J Hematol, 2005; 80: 64-69.
45. Ohshima K, Suzumiya J, Sugihara M, Nagafuchi S, Ohga S, Kikuchi M. CD95 (Fas) ligand expression of Epstein-Barr virus (EBV)-infected lymphocytes: a possible mechanism of immune evasion in chronic active EBV infection. Pathol Int, 1999; 49: 9-13.
46. Ohga S, Nomura A, Takada H, Ihara K, Kawakami K, Yanai F, Takahata Y, Tanaka T, Kasuga N, Hara T. Epstein-Barr virus (EBV) load and cytokine gene expression in activated T cells of chronic active EBV infection. J Infect Dis, 2001; 183: 1-7.
47. Kimura H, Hoshino Y, Hara S, Sugaya N, Kawada J, Shibata Y, Kojima S, Nagasaka T, Kuzushima K, Morishima T. Differences between T cell-type and natural killer cell-type chronic active Epstein-Barr virus infection. J Infect Dis, 2005; 191: 531-539.
48. Kimura H, Miyake K, Yamauchi Y, Nishiyama K, Iwata S, Iwatsuki K, Gotoh K, Kojima S, Ito Y, Nishiyama Y. Identification of Epstein-Barr virus (EBV)-infected lymphocyte subtypes by flow cytometric in situ hybridization in EBV-associated lymphoproliferative diseases. J Infect Dis, 2009; 200: 1078-1087.
49. Kawabe S, Ito Y, Gotoh K, Kojima S, Matsumoto K, Kinoshita T, Iwata S, Nishiyama Y, Kimura H. Application of flow cytometric in situ hybridization assay to Epstein-Barr virus (EBV)-associated T/NK lymphoproliferative diseases. Cancer Sci, 2012; 103: 1481-1488.
50. Gotoh K, Ito Y, Shibata-Watanabe Y, Kawada J, Takahashi Y, Yagasaki H, Kojima S, Nishiyama Y, Kimura H. Clinical and virological characteristics of 15 patients with chronic active Epstein-Barr virus infection treated with hematopoietic stem cell transplantation. Clin Infect Dis, 2008; 46: 1525-1534.
51. Sato E, Ohga S, Kuroda H, Yoshiba F, Nishimura M, Nagasawa M, Inoue M, Kawa K. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan. Am J Hematol, 2008; 83: 721-727.
52. Kawa K, Sawada A, Sato M, Okamura T, Sakata N, Kondo O, Kimoto T, Yamada K, Tokimasa S, Yasui M, Inoue M. Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection. Bone Marrow Transplant, 2011; 46: 77-83.
53. Iwatsuki K, Xu Z, Takata M, Iguchi M, Ohtsuka M, Akiba H, Mitsuhashi Y, Takenoshita H, Sugiuchi R, Tagami H, Kaneko F. The association of latent Epstein-Barr virus infection with hydroa vacciniforme. Br J Dermatol, 1999; 140: 715-721.
54. Barrionuevo C, Anderson VM, Zevallos-Giampietri E, Zaharia M, Misad O, Bravo F, Caceres H, Taxa L, Martinez MT, Wachtel A, Piris MA. Hydroa-like cutaneous T-cell lymphoma: a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. Appl Immunohistochem Mol Morphol, 2002; 10: 7-14.
55. Chen HH, Hsiao CH, Chiu HC. Hydroa vacciniforme-like primary cutaneous CD8-positive T-cell lymphoma. Br J Dermatol, 2002; 147: 587-591.
56. Cho KH, Lee SH, Kim CW, Jeon YK, Kwon IH, Cho YJ, Lee SK, Suh DH, Chung JH, Yoon TY, Lee SJ. Epstein-Barr virus-associated lymphoproliferative lesions presenting as a hydroa vacciniforme-like eruption: an analysis of six cases. Br J Dermatol, 2004; 151: 372-380.
57. Iwatsuki K, Satoh M, Yamamoto T, Oono T, Morizane S, Ohtsuka M, Xu ZG, Suzuki D, Tsuji K. Pathogenic link between hydroa vacciniforme and Epstein-Barr virus-associated hematologic disorders. Arch Dermatol, 2006; 142: 587-595.
58. Hirai Y, Yamamoto T, Kimura H, Ito Y, Tsuji K, Miyake T, Morizane S, Suzuki D, Fujii K, Iwatsuki K. Hydroa Vacciniforme Is Associated with Increased Numbers of Epstein-Barr Virus-Infected gammadeltaT Cells. J Invest Dermatol, 2012; 132: 1401-1408.
59. Tanaka C, Hasegawa M, Fujimoto M, Iwatsuki K, Yamamoto T, Yamada K, Kawa K, Saikawa Y, Toga A, Mase S, Wada T, Takehara K, Yachie A. Phenotypic analysis in a case of hydroa vacciniforme-like eruptions associated with chronic active Epstein-Barr virus disease of gammadelta T cells. Br J Dermatol, 2012; 166: 216-218.
60. Kaufmann SH. gamma/delta and other unconventional T lymphocytes: what do they see and what do they do? Proc Natl Acad Sci USA, 1996; 93: 2272-2279.